Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Abbott's Emerging Markets Strategy Gets A Bump With Piramal Buy

This article was originally published in The Pink Sheet Daily

Executive Summary

Abbott will gain Piramal's branded generics unit, expected to generate more than $500 million in sales in 2011.

You may also be interested in...

Deals Of The Week: Will Heated Competition To Buy Out Ache Laboratorios Muddy The Brazilian Waters?

Pfizer, Novartis and Abbott reportedly are battling to buy out family-owned Ache, Brazil’s leader in prescription drug sales. Plus deals involving AstraZeneca and AlphaCore, Pfizer and Bind Therapeutics and Merck and Ra Pharma.

Abbott Ups Emerging Markets Ante With Zydus Deal, Established Products Unit

Abbott licenses 24 drugs from Zydos and forms an Established Products Division focused on emerging markets.

Piramal Close To Buying Local Critical Care Brands With An Eye On Global Markets

MUMBAI - Indian drug maker Piramal Healthcare's ambition to grow into a world player in hospital and critical care products is set to cross another milestone with the likely acquisition of a few brands in the anesthesia segment from an unlisted Indian pharmaceutical company

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts